Kornimate/medical-research-clean huggingface dataset:
an online compassionate imagery intervention for veterinarian mental health

Conditions: Compassion; Perfectionism; Rumination; Self-Criticism; Resilience

Summary: this randomised control trial aims to determine the efficacy of a two-week, online compassionate imagery intervention on improving veterinarian mental wellbeing. participants will be randomly allocated to receive the intervention immediately or after a 10-week study period. self-report questionnaires will be used at four time points to measure change on a range of psychological variables.

background: research suggests that veterinarians are high-achievers with self-critical, perfectionist tendencies (holden, 2020). perfectionism in veterinarians has been associated with stress, anxiety, negative affect and low resilience (crane, phillips \& karin, 2015). however, mcarthur et al. (2017) found that veterinarians with higher levels of self-compassion reported greater resilience. a feasibility study by wakelin, perman and simonds (2022) found an online two-week compassion-focused imagery intervention to be acceptible and feasible for a veterinarian sample. wakelin et al. (2022) also reported indications of preliminary effect as veterinarians illustrated a reduction in perfectionism, work-related rumination and self-criticism over the intervention period. aim: this study aims to extend wakelin et al.'s (2022) research, to determine the efficacy of a two-week, online compassionate imagery intervention on improving veterinarian mental wellbeing. design: the study will use a mixed-methods, repeated measures, randomised controlled trial design. the independent variables will be the intervention group (either treatment or wait list control) and the data collection time point. six questionnaires will be used to collect quantitative data on the following dependent variables: perfectionism, work- related rumination, fear of compassion, resilience, self-compassion, self- criticism and self-reassurance. method: participants will complete questionnaire measures at four time points: prior to randomisation (baseline), two weeks post-randomisation (post-intervention), six-weeks post-randomisation (one-month intervention follow-up) and ten-weeks after randomisation (two-month intervention follow up). participants in the treatment group will be asked to watch a 10-15 minute compassionate imagery video every day for two weeks (14 in total). participants in the control group will gain access to intervention materials upon study completion but their engagement in the videos will not be monitored.

Eligibility criteria:
inclusion criteria: * any student, recent graduate or qualified veterinary surgeon will be eligible for participation in the study. exclusion criteria: * veterinarians who participated in wakelin et al.'s (2022) feasibility trial. * veterinarians who are currently receiving a compassion- or cognitive-based therapy.
treatment for patients with osteoarthritis (oa) of the knee

Conditions: Osteoarthritis

Summary: the purpose of this study is to evaluate the clinical response in subjects with symptomatic oa of the knee following a single 50 mg anakinra, 150 mg anakinra or placebo intra-articular (ia) injection.


Eligibility criteria:
inclusion criteria: - diagnosed with knee oa as determined by american college of rheumatology (acr) criteria - pain defined by a level of greater than 30 mm on a 100 mm visual analogue scale (vas) - no evidence of active effusion or inflammatory flare, confirmed by investigator - must exhibit radiographic evidence of tibio-femoral compartment knee oa within 12 months of screening - stable doses of any non-prescribed supplements (e.g. glucosamine or chondroitin sulphate, shark cartilage, diacerhein, soya extract) for at least 2 months prior to screening - unchanged use of physical therapy, biomechanical devices or orthotic support within at least 2 months of screening - subjects on nonsteroidal anti-inflammatory drug (nsaid) therapy must discontinue nsaids 3 days prior to baseline (day 1) - before any study-specific procedure is performed, the appropriate written informed consent for participation in the study must be obtained exclusion criteria: - malignancy within the previous 5 years, except for basal cell or in situ cancer - significant hematologic disease - active infection or history of recurrent or chronic infections - known diagnosis of hiv, hepatitis b, or hepatitis c infection - uncontrolled diabetes or cardiovascular disease and hypertension - inflammatory arthropathy including secondary oa - isolated oa of the patellofemoral joint (bi or tri-compartmental involvement are not exclusions) - end-stage ("bone-on-bone") oa (kellgren lawrence score of 4) - oa of the hip ipsilateral to the index knee - total white cell count less than 2.0 x 109/l and/or platelet count less than 100 x 109/l observed within 1 month preceding screening - prior ia injection of anakinra or experimental interleukin-1 (il-1) inhibitor therapy - concurrent treatment with subcutaneous (sc) anakinra - concurrent or recent (less than or equal to 1 month) use of experimental therapy - prior ia corticosteroid injection within 1 month of study - prior viscosupplement therapy within 3 months of study - contraindication(s) to ia injections - subjects who are pregnant or breast-feeding, or plan to become pregnant during the study - subject is not using adequate contraception - known allergy to e coli-derived products - unable to understand informed consent - concerns regarding subject's compliance with the protocol procedures - subject will not be available for follow-up assessment - active substance abuse

Keywords: intra-articular osteoarthritis oa anakinra amgen
complex motor learning with motor imaginary

Conditions: Learning Disturbance

Summary: subjects participate in a motor learning training with a special bicycle. the experimental group proceed with 15 minutes of physical training with the bicycle and 15 minutes of rest where they use motor imaginary. the control group proceed equal except for the motor imaginary intervention.

subjects participate in a motor learning training with a special bicycle. the experimental group proceed with 15 minutes of physical training with the bicycle and 15 minutes of rest where they use motor imaginary. the control group proceed equal except for the motor imaginary intervention. participants will be controlled for vestibular system previous participation.

Eligibility criteria:
inclusion criteria: * age between 18 and 29 years old * asymptomatic exclusion criteria: * subjects with pain * in medical treatment * diagnosed of any disease
closed-loop control of glucose levels (artificial pancreas) for 5 days in adults with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. the main objective of this project is to compare the efficacy of single-hormone closed-loop strategy and sensor-augmented pump therapy to regulate glucose levels in outpatient settings for 5 consecutive days in adults with type 1 diabetes. the investigators hypothesized that single-hormone closed-loop strategy will increase the time spent in the target range compared to sensor-augmented pump therapy.


Eligibility criteria:
inclusion criteria: 1. males and females ≥ 18 years of old. 2. clinical diagnosis of type 1 diabetes for at least one year. 3. the subject will have been on insulin pump therapy for at least 3 months. 4. hba1c ≤ 10%. 5. live in the area of montreal. exclusion criteria: 1. clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator. 2. recent (\< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. 3. warfarin chronic treatment if inr monitoring cannot be evaluated (can increase the risk of bleeding) 4. pregnancy (ongoing or current attempt to become pregnant). 5. severe hypoglycemic episode within two weeks of screening. 6. current use of glucocorticoid medication (except low stable dose and inhaled steroids). 7. known or suspected allergy to the trial products 8. other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator. 9. anticipating a significant change in exercise regimen between admissions (i.e. starting or stopping an organized sport).

Keywords: closed-loop system artificial pancreas type 1 diabetes hypoglycemia insulin
corticosteroids in community-acquired pneumonia

Conditions: Community-acquired Pneumonia

Summary: the purpose of this study is to determine the efficacy of addition of corticosteroid therapy to antibiotics in children hospitalized with community-acquired pneumonia. the hypothesis is that the use of corticosteroids decreases the length of stay in children hospitalized with community-acquired pneumonia.

community-acquired pneumonia (cap) is a common problem in pediatric practice. the lower respiratory tract infections, particularly pneumonia, are a frequent cause of morbidity in children and is the leading cause of mortality in developing countries. in the last 20 years, despite several research, only a small decrease in morbidity and mortality has been achieved. corticosteroids have an immune-modulation effect, not completely elucidated. most likely, this effect is due to down regulation of pro-inflammatory cytokines. we postulate that adding corticosteroids to antibiotic treatment of cap might change the immune response and thereby reduce morbidity, leading to a decrease in patients hospital length of stay.

Eligibility criteria:
inclusion criteria: * children hospitalized for community-acquired pneumonia * 2-18 years old exclusion criteria: * pulmonary chronic disease (including asthma) * immunodeficiency * diseases wich requires corticosteroids therapy (i.e. rheumatic diseases) * wheezing in current disease * previous hospitalization (14 days prior to admission) * pleural effusion on admission * malnutrition

Keywords: community-acquired pneumonia children respiratory infections
effects of lansoprazole on bone turnover markers

Conditions: Bone Turnover Rate Disorder; Calcium Metabolism Disorders

Summary: use of proton pump inhibitors (ppi) has increased in recent years. there are concerns that ppis have possible negative effects on bone metabolism. it has been suggested that ppis may reduce the absorption of calcium from the small intestine and lead to bone resorption by affecting osteoclastic activity. in this study, it is planned to investigate the effects of lansoprazole, a proton pump inhibitor, on bone turnover markers in pediatric patients with gastroesophageal reflux or gastroesophageal reflux disease.

this study is planned to be conducted with children who are diagnosed with gastroesophageal reflux or gastroesophageal reflux disease aged 2-18 years and healthy volunteers. the diagnosis of gastroesophageal reflux will be made in accordance with the guidelines of north american society for pediatric gastroenterology, hepatology, and nutrition (naspghan) and european society for pediatric gastroenterology, hepatology, and nutrition (espghan). written and verbal consent will be obtained from patients/healthy volunteers and/or parents who want to participate in the study. serum calcium, magnesium, alkaline phosphatase, parathormone, 25-oh vitamin d and osteocalcin and urine calcium, creatinine, deoxypyridinoline, c-terminal telopeptides type-1 collagen and n- terminal telopeptides type-1 collagen levels will be measured at baseline and second month in study group and once in control groups.

Eligibility criteria:
inclusion criteria: • patients diagnosed with gastroesophageal reflux or gastroesophageal reflux disease aged 16 to18 years. exclusion criteria: * patients with a malabsorptive disease. * patients with any chronic disease. * patients who use any medication that may affect calcium and bone metabolism. * patients who used proton pumps inhibitor within the last 3 months. * patients who do not use lansoprazole in the study group. * patients whose blood and urine samples are not taken in the eighth week of treatment.

Keywords: lansoprazole bone turnover gastroesophageal reflux
a clinical trial to evaluate the safety and efficacy of zyh7 compared to fenofibrate in patients with dyslipidemia

Conditions: Hypertriglyceridemia; Dyslipidemia

Summary: zyh7, a novel peroxisome proliferator-activated receptor (ppar) alpha agonist, is expected to decrease triglyceride level and also correct dyslipidemia.


Eligibility criteria:
inclusion criteria: 1. age 18-65 years 2. subjects of either gender, males or females 3. triglycerides between 200 to 500 mg/dl on screening visit. 4. body mass index (bmi) \> 23 kg/m2 5. if subject is diabetic, he should be controlled on a maximum of two oral anti diabetic agents except thiazolidinedione. 6. subject has given informed consent for participation in this trial. exclusion criteria: 1. pregnancy and lactation. 2. history of 5% weight loss in past 6 months. 3. subjects on treatment with insulin and ppar alpha or gamma agonist in the past 3 month. 4. subjects having unstable angina, acute myocardial infarction in past 3 months or heart failure of new york heart association (nyha) class (iii-iv). 5. uncontrolled hypertension (150/100 mm of hg).(if subject using thiazides, ace inhibitors, beta blockers they should be on minimum 3 month stable therapy and treatment not expected to change during trial participation) 6. history of clinically significant edema. 7. history of pancreatitis or gall stone diseases. 8. subject having thyroid-stimulating hormone (tsh) levels outside normal reference range, subjects who are clinically euthyroid and on stable thyroid replacement therapy for 2 months prior to screening and who are anticipated to remain on this dose throughout the trial period will be allowed. 9. uncontrolled diabetes (hba1c ≥ 9 gm %). 10. history of active liver disease or hepatic dysfunction demonstrated by aspartate aminotransferase (ast) and alanine aminotransferase(alt) ≥ 2.5 times of upper normal limit (unl) or bilirubin ≥ 2 times unl in the past 3 months. 11. renal dysfunction demonstrated by abnormal glomerular filtration rate (gfr) (60 ml/min) or presence of ketonuria. 12. history of myopathies or evidence of active muscle diseases demonstrated by creatinine phosphokinase(cpk) ≥ 10 times unl. 13. history of any other concurrent serious illness (e.g. tuberculosis, human immunodeficiency virus(hiv) infection, malignancy, etc). 14. history of alcohol and/or drug abuse. 15. history of known allergy, sensitivity or intolerance to the study drugs and their formulation ingredients. 16. subjects on any other lipid lowering medications. (appendix i). 17. if on contraceptive or hormone replacement therapy (hrt), therapy started or changed in last 3 months. 18. prolonged use of steroids (15 days) in last 3 months (topical preparations, nasal and intra-articular administration are permitted). 19. history of long term use of non-steroidal anti-inflammatory drugs. (1 month) 20. participation in any other clinical trial in the past 3 months 21. unable to give informed consent and follow protocol requirements.

Keywords: hypertriglyceridemia dyslipidemia
biological skin graft with keratinocyte-stem cell co-cultre for burn patients

Conditions: Burn Degree Second; Burn Degree Third

Summary: the goal of this clinical trial is to test whether artificial skin graft can substitute autologous skin graft in current burn treatment. the main question it aims to answer is: • can artificial skin graft result in better wound healing compared to the current burn treatment; autologous skin graft? you will: * undergo debridement surgery * receive artificial skin graft as an alternative to autologous skin graft * undergo biopsy procedure of burn area if there is a comparison group: researchers will compare autologous skin graft group to see the wound healing process

burn caused by working accidents occurs mostly in the male population of productive age (68.68%). up to this date, the only treatment for grade 2b-3 burns patients in indonesia is skin transplantation taken from their own body (autologous skin graft). this treatment has several drawbacks in which repeated surgery is sometimes necessary, the source of skin in patients with wide area of burn is limited, and patients that are in the elder age and have comorbidities have high mortality risk. in order to find an alternative for autologous skin graft therapy, a combination of tissue engineering and stem cell therapy is used to invent an artificial skin graft. the present study attempts to evaluate the efficacy of artificial skin graft seeded with autologous keratinocyte and stem cells towards wound healing in burn patients. the artificial graft used in this study is amnion bilayer; a graft that was decellularized to remove donor's cells and then layered to form into 3-d. to evaluate the efficacy, biopsies are taken from the burn area of patients to evaluate the histoarchitecture of patients' tissue by histological staining (h\&e and movat's pentachrome, ihc collagen i, collagen iii, vwf, and alpha-sma) and measure the relative gene expression by qpcr. for clinical data, burn area calculation using rule of 9 method and thermography measurement using flirone. furthermore, systemic evaluation of patients are done by monitoring the procalcitonin, lactate, mean arterial pressure, gradation of wound, and sensory of burn area. the evaluation and measurement mentioned above are then compared to patients treated with the current available therapy; autologous skin graft. the artificial skin graft is hoped to result in equal, if not better, wound healing in burn patients compared to autologous skin graft. the investigators hope that artificial skin graft can be an option, other than autologous skin graft, in treating burn patients in the future.

Eligibility criteria:
inclusion criteria: * aged 18 - 55 * area of burn \<50% * acute phase burn (\<120 hrs) * have not undergo any surgery for burn treatment exclusion criteria: * immunocompromised * have comorbidities

Keywords: artificial skin graft keratinocyte amnion epithelial stem cells burn
nectin-4 specific lmw pet probe imaging in urothelial carcinoma

Conditions: Urothelial Carcinoma

Summary: to evaluate the ability of \[68ga\]n188 to detect nectin-4 overexpression in patients with urothelial carcinoma, especially in patients with recurrent or advanced bladder cancer.


Eligibility criteria:
inclusion criteria: 1. 18-75 years old, male or female; 2. heart function is normal; 3. normal heart function; 4. estimated survival ≥12 weeks; 5. good follow-up compliance; 6. presence of at least one measurable target lesion according to recist1.1 criteria; 7. women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting the test; fertile men and women must agree to use effective contraception to prevent pregnancy during the study period and for 3 months after the test; 8. patients recommended by clinicians to undergo pet/ct examination for tumor diagnostic staging; 9. the subject patients could fully understand and voluntarily participate in the experiment, and signed the informed consent. exclusion criteria: 1. serious abnormality of liver, kidney and blood; 2. pregnant patients; 3. pregnant and lactation women; 3) unable to lie flat for half an hour; 4) refuse to join the clinical investigator; 5) suffering from claustrophobia or other mental diseases; 6) other conditions that researchers deem unsuitable for participating in the experiment.
evaluation of weekly idrabiotaparinux sodium versus oral adjusted-dose warfarin to prevent stroke and systemic thromboembolic events in patients with atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the objective is to evaluate whether once weekly subcutaneous (sc) injection of idrabiotaparinux sodium (biotinylated idraparinux) is at least as efficient to prevent clots in brain and in the other organs than oral international normalized ratio (inr) adjusted-dose warfarin in patients with atrial fibrillation (af).

the end of the study is defined by a common study end date for all participants, defined as 9 months (39 weeks) after the last participant randomized. all participants will receive oral warfarin (or matching placebo) and weekly sc injections of idrabiotaparinux sodium (or matching placebo) up to 6 months before the common study end date. all participants are expected to be treated for at least 6 months. all participants will have then an 6-month observational period after cessation of study treatment.

Eligibility criteria:
inclusion criteria: * non valvular atrial fibrillation (af) * indication for long-term vitamin-k antagonist (vka) therapy based on the presence of previous ischemic stroke, transient ischemic attack (tia) or systemic embolism and/or at least two of the following risk factors: hypertension requiring drug treatment, moderately or severely impaired left ventricular function and/or congestive heart failure, age \> or = 75 years, diabetes mellitus. main exclusion criteria: * indication for vka other than af * stroke or tia within previous 5 days * transient af caused by a reversible disorder * planned major surgery/trauma or cardioversion within 30 days * inr \> 3 at baseline * active bleeding or high risk of bleeding * uncontrolled hypertension * pregnancy or childbearing potential without proper contraceptive measures or breast feeding.

Keywords: stroke systemic thromboembolic events
a prospective, multicenter, single-arm mac-pd cohort: a ntm-net and esgmyc collaborative study

Conditions: Mycobacterium Avium Complex Pulmonary Disease

Summary: to gain insight in the effectiveness of, adherence and adjustments to guideline-based three-drug antimycobacterial therapy in patients with mycobacterium avium complex pulmonary disease (mac-pd) during the first 6 months of treatment.

mycobacterium avium complex (mac) is the most frequent causative species that results in nontuberculous mycobacterial pulmonary disease (ntm-pd). current treatment outcomes for mac-pd are unsatisfactory with sputum culture conversion rates between 50-70%.the high prevalence of drug toxicity and low adherence to guideline-based treatment (gbt) are key reasons for the limited treatment success. hence, there is an unmet need for prospective data on effectiveness of, adherence and adjustments to mac-pd treatment regimens. by collaborating with ntm-net and esgmyc affiliated medical centers, we enable systematic, prospective data collection of an international mac-pd cohort.

Eligibility criteria:
inclusion criteria: * newly diagnosed mac-pd (primary or recurrent) as per the international ntm guideline that requires three-drug antimycobacterial treatment * signed and dated informed consent exclusion criteria: * the participant is in poor general condition where participation in the study cannot be accepted per discretion of the investigator * the participant has a known or suspected, current drug or alcohol abuse, that is, in the opinion of the investigator, sufficient to compromise the safety or cooperation of the patient * hiv-infection; * cystic fibrosis; * \>1 month antibiotic treatment for current mac infection; * \< 6 months between previous antimycobacterial ntm-pd treatment and antimycobacterial treatment for current mac-pd * disseminated mac infection; * active pulmonary tuberculosis, fungal or nocardial disease requiring treatment; * active pulmonary malignancy (primary or metastatic) or any other malignancy requiring chemotherapy or radiotherapy within 6 months before screening or anticipated during the study period;